OBJECTIVES: A SWOG/GOG phase 3 trial exploring the impact of 12-monthly cycles of paclitaxel given to patients with advanced ovarian cancer who achieved a complete response to primary chemotherapy was discontinued by the Data Safety and Monitoring Committee when a prospectively defined interim analysis revealed a highly statistically significant improvement in progression-free survival (PFS). At study closure, it was too early to assess the impact on overall survival. METHODS:Patients (n=296) received either 3 or 12 monthly cycles of paclitaxel (175 mg/m(2) over 3 h). RESULTS: Of the 146 patients on the 3-cycle arm, 9 (6%) received >3 cycles. Median (12 versus 3 cycles; intention-to-treat analysis) updated PFS (all pts) 22 versus 14 months, p=0.006; overall survival (all pts) 53 versus 48 months, p=0.34. CONCLUSION: Twelve cycles of single agent maintenance paclitaxel significantly improves PFS. Explanations for the lack of a favorable influence on overall survival include: (a) treatment at relapse equalized outcome; (b) the sample size was insufficient to reveal a difference; (c) "crossover" of patients from 3 cycles to longer treatment masked a potential difference. An ongoing phase 3 trial will hopefully provide a definitive answer to the question of the impact of this maintenance strategy on overall survival.
RCT Entities:
OBJECTIVES: A SWOG/GOG phase 3 trial exploring the impact of 12-monthly cycles of paclitaxel given to patients with advanced ovarian cancer who achieved a complete response to primary chemotherapy was discontinued by the Data Safety and Monitoring Committee when a prospectively defined interim analysis revealed a highly statistically significant improvement in progression-free survival (PFS). At study closure, it was too early to assess the impact on overall survival. METHODS:Patients (n=296) received either 3 or 12 monthly cycles of paclitaxel (175 mg/m(2) over 3 h). RESULTS: Of the 146 patients on the 3-cycle arm, 9 (6%) received >3 cycles. Median (12 versus 3 cycles; intention-to-treat analysis) updated PFS (all pts) 22 versus 14 months, p=0.006; overall survival (all pts) 53 versus 48 months, p=0.34. CONCLUSION: Twelve cycles of single agent maintenance paclitaxel significantly improves PFS. Explanations for the lack of a favorable influence on overall survival include: (a) treatment at relapse equalized outcome; (b) the sample size was insufficient to reveal a difference; (c) "crossover" of patients from 3 cycles to longer treatment masked a potential difference. An ongoing phase 3 trial will hopefully provide a definitive answer to the question of the impact of this maintenance strategy on overall survival.
Authors: T B Hakes; E Chalas; W J Hoskins; W B Jones; M Markman; S C Rubin; D Chapman; L Almadrones; J L Lewis Journal: Gynecol Oncol Date: 1992-06 Impact factor: 5.482
Authors: T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman Journal: Cancer Res Date: 2000-04-01 Impact factor: 12.701
Authors: K Bertelsen; A Jakobsen; J Strøyer; K Nielsen; E Sandberg; J E Andersen; S Ahrons; M Nyland; P Hjortkjaer Pedersen; G Larsen Journal: Gynecol Oncol Date: 1993-04 Impact factor: 5.482
Authors: Maurie Markman; P Y Liu; Mace L Rothenberg; Bradley J Monk; Mark Brady; David S Alberts Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Sabino De Placido; Giovanni Scambia; Giovanni Di Vagno; Emanuele Naglieri; Alessandra Vernaglia Lombardi; Rosalbino Biamonte; Marco Marinaccio; Giacomo Cartenì; Luigi Manzione; Antonio Febbraro; Andrea De Matteis; Gianpietro Gasparini; Maria Rosaria Valerio; Saverio Danese; Francesco Perrone; Rossella Lauria; Michele De Laurentiis; Stefano Greggi; Ciro Gallo; Sandro Pignata Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Maurie Markman; P Y Liu; Sharon Wilczynski; Bradley Monk; Larry J Copeland; Ronald D Alvarez; Caroline Jiang; David Alberts Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Lisa M Hess; Nan Rong; Patrick O Monahan; Paridha Gupta; Champ Thomaskutty; Daniela Matei Journal: Cancer Date: 2010-11-15 Impact factor: 6.860
Authors: Katherine C Fuh; James J Java; John K Chan; Daniel S Kapp; Bradley J Monk; Robert A Burger; Robert C Young; David S Alberts; William P McGuire; Maurie Markman; Jeffrey Bell; Robert F Ozols; Deborah K Armstrong; Carol Aghajanian; Michael A Bookman; Robert S Mannel Journal: Gynecol Oncol Date: 2019-06-19 Impact factor: 5.482